WASHINGTON – AdvaMed, the world’s leading medical technology association, announced that Ashley McEvoy, Executive Vice President and Worldwide Chairman of Medtech at Johnson & Johnson, was elected Chairman of the AdvaMed Board of Directors for a two-year term beginning today.

McEvoy has served on the AdvaMed Board of Directors since 2018. She has led important initiatives for the Association, including overseeing AdvaMed efforts to expand and strengthen global market access for U.S. medtech firms through her leadership of the International Board Committee; work to ensure a safe restoration of elective procedures during the pandemic; and, most recently, leading the Board’s efforts to address disparities in health care access and outcomes reflected in the association’s Principles on Health Equity. She succeeds Abiomed’s former Chairman, President, and CEO Michael R. Minogue.

McEvoy currently leads Johnson & Johnson’s $27 billion Medtech business where she has strengthened its leading portfolio across surgery, orthopedics, interventional solutions, and vision. With a presence in almost every operating room in the world, and in more than 75 million procedures annually, Johnson & Johnson Medtech is driving patient-centric innovation around the world.

Ashley and the global Johnson & Johnson Medtech team were recognized by Fast Company as one of the most innovative companies of 2022. Ashley was also recently honored as one of 50 individuals named to Forbes’ inaugural CEO NEXT list and was ranked #1 on the Top 25 Women Leaders in Medical Devices list by The Healthcare Technology Report. She ranked #41 on Fortune’s Most Powerful Women List in 2019 and was named a Woman of Achievement in 2020 by the National Association of Female Executives for her dedication to advancing diversity, equity, and inclusion.

McEvoy said: “It’s an exciting time for the medtech industry, and I’m honored and grateful for the opportunity to serve as Chair of the AdvaMed Board of Directors. I’ve seen the impact AdvaMed has had on advancing policies that improve patient access to safe, effective, and innovative medical technologies and know we will continue to advance that mission. As Chair, I will build on the work of my predecessors to imagine new ways to improve patient health and elevate the standard of care through innovation, industry growth, and improved access for the patients we serve.”

The medtech association said McEvoy was unanimously elected by the AdvaMed Board of Directors at its quarterly meeting yesterday.

As is tradition for the incoming Chair, McEvoy shared with the Board her primary areas of focus during her upcoming two-year term. In addition to supporting AdvaMed’s Innovation Agenda to improve patient access to innovative new medical technologies, McEvoy said she will work with the Board and AdvaMed membership to:

• Build a more resilient healthcare system through policy enhancement and improved supply chain operations,
• Drive digital transformation in medtech through ethical policies that promote the responsible use of data, and
• Ensure the medtech industry reflects the patients it serves through programs that increase diverse representation and continue to improve diversity in clinical research.

AdvaMed President and CEO Scott Whitaker said of McEvoy: “Ashley McEvoy’s leadership across her long career in medtech and as a member of AdvaMed’s Board has prepared her well to lead the medtech industry as Board Chair. Her focus on helping to build a more resilient healthcare system, driving digital transformation, and making an impact for patients will help set our industry on the right path following the challenges of the pandemic. I know I speak for the entire Board when I say we look forward to a bright future for AdvaMed and the industry with Ashley at the helm. I look forward to working with her and the Board to help our companies to continue doing what they do best—improving and saving patients’ lives.”

Whitaker said of Minogue: “Mike became Chair in the middle of the pandemic, a tough time for this country and our healthcare system, and without question his leadership helped keep our industry strong and steady as it worked to meet the demands of the crisis. His focus on ‘Patients First,’ his efforts to improve the diversity of our industry, including helping our vets through Medtech Vets to find meaningful work in the medtech field, have left behind a legacy we will continue to build upon. I thank him for being a great friend—to the Board, to me, to the entire AdvaMed team.”

When Minogue became Chair of the AdvaMed Board, he said he planned to strengthen the association’s and industry’s focus on patients and the impact AdvaMed companies make in patients’ lives, and that he would build upon outgoing Chairman Kevin Lobo’s leadership and successful work to improve inclusion and diversity throughout the industry, with the added component of expanding the recruitment from our nation’s military veterans. As Chair, he also oversaw the negotiation and enactment of MDUFA V, which Whitaker called a “historic” agreement that “[set] the stage for a new era of innovation in health care, ensuring greater predictability, consistency, accountability, and communication between FDA and the medtech innovators who are changing the way patients seek and receive life-saving care.”

Minogue became a member of the AdvaMed Board of Directors in 2007 and a member of the Board Executive Committee in 2009, during which time he has served on several committees, including those overseeing membership, inclusion and diversity, payment policy, ethics, and international policy. In 2011, Mr. Minogue was elected as the first Chairman of the newly created Emerging Growth Company Council, which later became AdvaMed Accel, the division within AdvaMed dedicated to the needs of smaller medical technology manufacturers. Mr. Minogue served as the Chairman of the Accel Board of Directors until 2014. In 2012, Mr. Minogue and AdvaMed co-founded MedtechVets.org, and he served as Chairman until 2019.

Minogue served as Chairman, President, and CEO of Abiomed from 2004 until Abiomed was acquired by Johnson & Johnson late last year. Before that, he spent 11 years with General Electric Medical Systems, where he held numerous leadership positions and was awarded three patents. Mr. Minogue also served as an Infantry Officer in the U.S. Army, with multiple distinctions including Airborne, Ranger, Desert Storm Veteran, and Bronze Star. He received his Bachelor of Science degree in engineering management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago.